Pages

▼
Showing posts with label Clinical Trial Result. Show all posts
Showing posts with label Clinical Trial Result. Show all posts

Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis

›
Amgen and UCB announced positive top-line results for romosozumab from the pivotal Phase 3 place B o-cont R olled study evaluat I ng ...

PFIZER TO PRESENT NEW DATA ON INVESTIGATIONAL TOFACITINIB AT THE 11TH CONGRESS OF ECCO

›
Pfizer Inc announced today that seven abstracts reporting on new research for tofacitinib in ulcerative colitis (UC) and Crohn’s dis...

Baxter Enrolls First Patient in U.S. Clinical Trial for VIVIA Investigational Home Hemodialysis System

›
  Baxter International Inc announced enrollment of the first patient in a U.S. clinical trial for VIVIA, an investigational home hem...

GSK seeking Expanded Indication for FluLaval Quadrivalent in US

›
GSK announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for FLULAV...

Novartis announces efficacy of Cosentyx in ankylosing spondylitis patients

›
Novartis announced that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondyliti...

GeNeuro Launches Phase IIb study “CHANGE-MS”

›
GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced that it has initiated its planned Phase IIb stud...

Novo Nordisk completes fourth phase 3a trial with semaglutide

›
Novo Nordisk announced the headline results from the fourth phase 3a trial for semaglutide, SUSTAIN2. Semaglutide is a new GLP-1 analogue a...

Boehringer Ingelheim Started safety of OFEV Study

›
Boehringer Ingelheim announces the initiation of clinical trial, a new 12 week study to assess the safety, tolerability and pharmacokinetic...

Merck Decides Not to Pursue Evofosfamide

›
Merck    announced that it is not planning to file for approval of evofosfamide in advanced soft tissue sarcoma and advanced pancreatic ade...

AbbVie released PHASE 1 Clinical Data of VENETOCLAX

›
AbbVie  announced the online publication of new data in the New England Journal of Medicine (NEJM) showing some patients with relapsed/refr...

EISAI TO PRESENT LATEST DATA ON FYCOMPA

›
Eisai Co., Ltd announced that the latest data on its in-house developed AMPA receptor antagonist Fycompa® (perampanel hydrate, “perampanel...

Allergan and Gedeon Richter Plc. to Present Data on VRAYLAR

›
Allergan plc and Gedeon Richter Plc. announced they will present data on VRAYLAR (cariprazine) in patients with schizophrenia during the 54...

Astellas and Ironwood Present Top - Line Data from Phase III IBS - C Trial

›
Astellas Pharma and Ironwood Pharmaceuticals announced that the Phase III clinical trial of Linaclotide conducted in Japan in adults with i...

Novartis presents new data on advanced breast cancer

›
Novartis will present data that highlight advancements in targeted combination therapy research, and underscore the company's continued...

Amgen to Present IMLYGIC Data

›
Amgen announced that the Company will present eight IMLYGIC (talimogene laherparepvec) abstracts, including data from the Phase 3 trial a...

AbbVie Announces Phase 2 Studies ABT-493

›
AbbVie announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, ...

GSK announces positive results of Benlysta

›
GSK announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lupus erythematos...

Pfizer to Present New Data on Eliquis

›
Bristol Myers Squibb and Pfizer announced that 22 abstracts will be presented at the American Heart Association (AHA) Scientific Sessions ...

Novartis presents new two year data for Cosentyx

›
Novartis announced new results for Cosentyx ® (secukinumab) showing no further progression in joint damage in 84% of patients with psori...

ViiV Healthcare announces Results of HIV drug Regimen

›
ViiV Healthcare announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks.  These results show that th...